Phosphodiesterase type 5 inhibitors in treatment of lower urinary tract dysfunctions

Kuzmin, Igor V.; Валентинович, Кузьмин Игорь; Ajub, Abdul Kh.; Хамидович, Аюб Абдул; Slesarevskaya, M N; Николаевна, Слесаревская Маргарита

doi:10.17816/uroved10167-74

Cited by 7 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ингибиторы ФДЭ-5 используются в урологии с 1998 г. и хорошо зарекомендовали себя не только при лечении эректильной дисфункции, но и расстройств мочеиспускания [27][28][29]. В последние годы активно изучается возможность применения этих препаратов для лечения ПЭ, Таблица.…”

Section: Discussionunclassified

Tadalafil-SZ in the treatment of premature ejaculation in young age men: a comparative placebo-controlled study

Al-Shukri

Kostyukov

Maksimova

et al. 2022

Urology reports (St. - Petersburg)

View full text Add to dashboard Cite

BACKGROUND: The frequency of occurrence reaches premature ejaculation (PE) in young men reaches 30%. Increasing the effectiveness of treatment of patients with PE is one of the important problems of urology. AIM: Evaluation of the effectiveness of treatment of young patients with premature ejaculation with the phosphodiesterase 5-type inhibitor Tadalafil-SZ in monotherapy and in combination with behavioral therapy, as well as its comparison with the appointment of only behavioral therapy and placebo. MATERIALS AND METHODS: We observed 70 men with premature ejaculation aged 18 to 25 years. All patients were divided into 4 groups. Patients of the 1st group (n = 20) were prescribed Tadalafil-SZ at a dose of 5 mg once a day as monotherapy, patients of the 2nd group (n = 20) received behavioral therapy according to the startstop method; patients of the 3rd group (n = 20) were prescribed a combination therapy with Tadalafil-SZ at a dose of 5 mg per day together with the startstop behavioral technique; patients of the 4th group (n = 10) were prescribed a placebo. The duration of treatment is 30 days. Control examinations were performed before the start of treatment, immediately after its completion and 2 months after the end of therapy. To assess ejaculatory function the PEDT and AIPE questionnaires were used, as well as the IELT test. RESULTS: After the end of the 30-day course of treatment in patients of the 1st and 3rd groups, a significant increase in the duration of sexual intercourse by 22.5 times was noted compared with the values before treatment, as well as with the values in patients of the 4th group who received placebo. In patients of the 2nd group, we did not notice significant changes in comparison with the indicators before treatment in terms of the total scores of the PEDT questionnaire and the results of the IELT test, however, an increase in the total scores of the AIPE questionnaire was found. In patients of the 4th control group, there was no improvement in any of the tests performed. 2 months after the end of treatment, patients of the 1st group noted a return to the initial duration of sexual intercourse. The effect of the treatment was noted only in patients of the 3rd group, in whom during the control examination after 2 months the duration of sexual intercourse was significantly higher compared to the initial values before the start of treatment. CONCLUSIONS: The results of the study indicate the high efficiency of the phosphodiesterase 5-type inhibitor Tadalafil-SZ in the treatment of patients with premature ejaculation. The best results of treatment were achieved with the combined use of drug and behavioral therapy.

show abstract

Section: Discussionunclassified

Tadalafil-SZ in the treatment of premature ejaculation in young age men: a comparative placebo-controlled study

Al-Shukri

Kostyukov

Maksimova

et al. 2022

Urology reports (St. - Petersburg)

View full text Add to dashboard Cite

show abstract

“…Клинически это проявляется уменьшением числа мочеиспусканий, увеличением промежутков между ними, исчезновением императивных позывов и ургентного недержания мочи. В настоящее время для лечения ГМП используют лекарственные препараты разных фармакологических групп, однако основной остается антихолинергическая терапия [11][12][13][14].…”

Section: Introductionunclassified

Anticholinergic therapy of an overactive bladder: clinical practice aspects

Kuzmin¹,

Кузьмина²

2021

Russian Medical Inquiry

View full text Add to dashboard Cite

The review presents data on the epidemiology, clinical course and modern methods to the treatment of overactive bladder. It also describes the pharmacological bases of anticholinergic drug use, which are first-line in the treatment of this disease. The pharmacological and clinical aspects of the new M-holinoblocker, fesoterodine, are considered. The drug belongs to the competitive blockers of M2-and M3-cholinergic receptors. The conducted studies have shown the high clinical efficacy of fesoterodine. Due to the low lipophilicity and large molecular weight, the drug’s ability to penetrate the blood-brain barrier is minimal, which causes a low frequency of adverse events from the central nervous system. The pharmacokinetic and pharmacodynamic properties of fesoterodine allow it to be prescribed to "vulnerable" groups of patients — the elderly, patients with CNS diseases and cognitive disorders. According to the FORTA system, fesoterodine is the only antimuscarinic drug classified in category B. The results of a multiple-criteria decision-making showed a favorable benefit-risk profile of fesoterodine, prescribed according to a flexible dosage regimen of 4 mg and 8 mg. Important benefits of fesoterodine are the convenience of intake, the possibility of dose titration, as well as the ratio of treatment costs and its efficacy. The practical issues of using fesoterodine in various clinical cases are considered. KEYWORDS: overactive bladder, anticholinergic therapy, fesoterodine, multiple-criteria decision-making, FORTA classification. FOR CITATION: Kuzmin I.V., Kuzmina S.V. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273–279 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-273-279.

show abstract

Prostate diseases: pathogenetic bases and therapeutic possibilities of entomotherapy

Kuzmin

Slesarevskaya

2022

Androl. genit. hir.

View full text Add to dashboard Cite

The review article is devoted to the history of creation, biological effects and clinical application of the entomological drug Adenoprosin. The data of experimental studies are presented, indicating a high biological activity of the drug, the mechanisms of its therapeutic action are described. The pharmacological effects of Adenoprosin were analyzed, which ensure its high clinical efficacy and good tolerability. The pathogenetic validity of the appointment of Adenoprosin in patients with chronic prostatitis and benign prostatic hyperplasia was shown.

show abstract

Phosphodiesterase type 5 inhibitors in treatment of lower urinary tract dysfunctions

Cited by 7 publications

References 35 publications

Tadalafil-SZ in the treatment of premature ejaculation in young age men: a comparative placebo-controlled study

Tadalafil-SZ in the treatment of premature ejaculation in young age men: a comparative placebo-controlled study

Anticholinergic therapy of an overactive bladder: clinical practice aspects

Prostate diseases: pathogenetic bases and therapeutic possibilities of entomotherapy

Contact Info

Product

Resources

About